Clinical Research Coordinator -AstraZeneca India Pvt. Ltd-Bengaluru/Bangalore

ASTRAZENECA PHARMA INDIA is looking for Fresh B.PHARMA candidates for CTA/ CRC role to be based at Bangalore. Only Female candidates are eligible for the role. 

Here is the brief description of job profile.

Preparing and submitting study documents to sites
Coordinating with various vendors for translation and archival of study related documents
Updating various systems for study milestones
Preparing study files
Maintaining trial master files
Following up with the sites for essential documents
QC of essential documents

Candidate needs to have fantastic command over written and spoken English. Good IT skill particularly good knowledge of work, power point, and excel. Understanding of drug development knowledge and knowledge of pharmacology. Requisite qualification is BPharm.

Recruiter Name:Usha Bhatt

Email Address:

Website:http:// www.astrazeneca.com

Telephone:09902577714

Tumorigenesis: it takes a village

Although it is widely accepted that most cancers exhibit some degree of intratumour heterogeneity, we are far from understanding the dynamics that operate among subpopulations within tumours. There is growing evidence that cancer cells behave as communities, and increasing attention is now being directed towards the cooperative behaviour of subclones that can influence disease progression. As expected, these interactions can add a greater layer of complexity to therapeutic interventions in heterogeneous tumours, often leading to a poor prognosis. In this Review, we highlight studies that demonstrate such interactions in cancer and postulate ways to overcome them with better-designed therapeutic strategies.
Read More

Combination cancer immunotherapy and new immunomodulatory targets

Targeting immune checkpoints such as programmed cell death protein 1 (PD1), programmed cell death 1 ligand 1 (PDL1) and cytotoxic T lymphocyte antigen 4 (CTLA4) has achieved noteworthy benefit in multiple cancers by blocking immunoinhibitory signals and enabling patients to produce an effective antitumour response. Inhibitors of CTLA4, PD1 or PDL1 administered as single agents have resulted in durable tumour regression in some patients, and combinations of PD1 and CTLA4 inhibitors may enhance antitumour benefit. Numerous additional immunomodulatory pathways as well as inhibitory factors expressed or secreted by myeloid and stromal cells in the tumour microenvironment are potential targets for synergizing with immune checkpoint blockade. Given the breadth of potential targets in the immune system, critical questions to address include which combinations should move forward in development and which patients will benefit from these treatments. This Review discusses the leading drug targets that are expressed on tumour cells and in the tumour microenvironment that allow enhancement of the antitumour immune response.
Read More